JP2023549167A5 - - Google Patents
Info
- Publication number
- JP2023549167A5 JP2023549167A5 JP2023527966A JP2023527966A JP2023549167A5 JP 2023549167 A5 JP2023549167 A5 JP 2023549167A5 JP 2023527966 A JP2023527966 A JP 2023527966A JP 2023527966 A JP2023527966 A JP 2023527966A JP 2023549167 A5 JP2023549167 A5 JP 2023549167A5
- Authority
- JP
- Japan
- Prior art keywords
- nucleic acid
- mitochondrial
- acid molecule
- disease
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063110625P | 2020-11-06 | 2020-11-06 | |
| US63/110,625 | 2020-11-06 | ||
| PCT/US2021/058286 WO2022099034A2 (en) | 2020-11-06 | 2021-11-05 | Mitochondrial protein targeting engineered deubiquitinases and methods of use thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023549167A JP2023549167A (ja) | 2023-11-22 |
| JP2023549167A5 true JP2023549167A5 (cg-RX-API-DMAC7.html) | 2024-11-12 |
Family
ID=81458643
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023527966A Pending JP2023549167A (ja) | 2020-11-06 | 2021-11-05 | ミトコンドリアタンパク質ターゲティング操作脱ユビキチン化酵素およびその使用方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20240026330A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4240753A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2023549167A (cg-RX-API-DMAC7.html) |
| CN (1) | CN116802199A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2021376278A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3200982A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2022099034A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115998769B (zh) * | 2022-11-02 | 2025-12-09 | 中国人民解放军军事科学院军事医学研究院 | 以Mysm1基因为抑制靶标的物质在提高线粒体活性中的应用 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2012177549A (ja) * | 2009-06-24 | 2012-09-13 | Hokkaido Univ | 蛍光温度プローブおよびそれを用いた温度測定装置 |
| EP2992892A1 (en) * | 2014-09-05 | 2016-03-09 | Universität zu Köln | Fusion protein for use in the treatment of mitochondrial diseases |
| EP3706782A4 (en) * | 2017-11-06 | 2021-09-08 | The Trustees of Columbia University in the City of New York | COMPOSITIONS AND METHODS OF USING MANIPULATED DEUBIQUITINASES FOR PROBING UBIQUITIN-DEPENDENT CELL PROCESSES |
| WO2019126762A2 (en) * | 2017-12-22 | 2019-06-27 | The Broad Institute, Inc. | Cas12a systems, methods, and compositions for targeted rna base editing |
| AU2020224327B2 (en) * | 2019-02-21 | 2022-09-29 | Entact Bio Limited | Survival-targeting chimeric ( SURTAC) molecules |
-
2021
- 2021-11-05 WO PCT/US2021/058286 patent/WO2022099034A2/en not_active Ceased
- 2021-11-05 JP JP2023527966A patent/JP2023549167A/ja active Pending
- 2021-11-05 AU AU2021376278A patent/AU2021376278A1/en active Pending
- 2021-11-05 CN CN202180089240.1A patent/CN116802199A/zh active Pending
- 2021-11-05 US US18/251,850 patent/US20240026330A1/en active Pending
- 2021-11-05 CA CA3200982A patent/CA3200982A1/en active Pending
- 2021-11-05 EP EP21890166.8A patent/EP4240753A4/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3794024B1 (en) | Activatable interleukin-2 polypeptides and methods of use thereof | |
| US20220267400A1 (en) | Il-2 cytokine prodrugs comprising a cleavable linker | |
| EP4034551A1 (en) | Cytokine prodrugs and dual-prodrugs | |
| AU2003298187B2 (en) | Humanized antibody (H14.18) of the mouse 14.18 antibody binding to GD2 and its fusion with IL-2 | |
| EP2970512B1 (en) | Fusion immunomodulatory proteins and methods for making same | |
| EP1301605B1 (en) | Nk cells activating receptors and their therapeutic and diagnostic uses | |
| CN112654636A (zh) | 可活化白介素12多肽及其使用方法 | |
| KR20030048041A (ko) | 표적-특이적 프로드럭으로서 사용하기 위한항체-사이토카인-사이토카인 억제제로 이루어진 융합단백질(셀렉토카인) | |
| WO2017025698A1 (en) | Bispecific, cleavable antibodies | |
| WO1996010089A1 (en) | Modification of peptide and protein | |
| JP2023529368A (ja) | B7h3標的タンパク質及びその使用方法 | |
| AU2001278662A1 (en) | NK cells activating receptors and their therapeutic and diagnostic uses | |
| KR20240150525A (ko) | 조건부 활성 폴리펩티드 | |
| JPH0889278A (ja) | 遺伝子導入用修飾蛋白質及びその製法 | |
| JP2006517970A (ja) | 癌免疫療法のための組成物及び方法 | |
| TW202320838A (zh) | 誘導型細胞激素前藥及pd-1/pd-l1組合療法 | |
| KR20230160366A (ko) | 암 치료를 위한 her2/4-1bb 이중특이적 융합 단백질 | |
| JP2023549761A5 (cg-RX-API-DMAC7.html) | ||
| EP2091972B1 (en) | Multi-modal cancer therapy using viral hitch-hiking | |
| JP2023548973A5 (cg-RX-API-DMAC7.html) | ||
| US20230406927A1 (en) | Masked single-domain antibodies and methods thereof | |
| US20260103541A1 (en) | Paracrine Adenoviral Delivery of Biomolecules | |
| US20230340499A1 (en) | Constructs, compositions, cells and methods for increased recombinant protein expression by targeted integration and amplification | |
| US11028132B1 (en) | Half-life optimized linker composition | |
| JP2023551068A5 (cg-RX-API-DMAC7.html) |